Document is current
Any future updates will be listed below
-
Authors
Rhodin, Michael H. J. https://orcid.org/0000-0003-4032-7545
Reyes, Archie C.
Balakrishnan, Anand https://orcid.org/0000-0002-5778-3857
Bisht, Nalini
Kelly, Nicole M.
Gibbons, Joyce Sweeney
Lloyd, Jonathan
Vaine, Michael
Cressey, Tessa
Crepeau, Miranda
Shen, Ruichao
Manalo, Nathan
Castillo, Jonathan
Levene, Rachel E.
Leonard, Daniel
Zang, Tianzhu
Jiang, Lijuan
Daniels, Kellye
Cox, Robert M. https://orcid.org/0000-0003-0620-1674
Lieber, Carolin M.
Wolf, Josef D. https://orcid.org/0000-0003-2507-6944
Plemper, Richard K. https://orcid.org/0000-0003-2034-2107
Leist, Sarah R. https://orcid.org/0000-0002-4989-5381
Scobey, Trevor
Baric, Ralph S. https://orcid.org/0000-0001-6827-8701
Wang, Guoqiang
Goodwin, Bryan
Or, Yat Sun
- License Information
-
More Information
Article History
Received: 21 December 2023
Accepted: 23 July 2024
First Online: 1 August 2024
Competing interests
: M.H.J.R., A.C.R., A.B., N.B., N.M.K., J.S.G., J.L., M.V., T.C., M.C., R.S., N.M., J.C., R.E.L., D.L., T.Z., L.J., K.D., G.W., B.G, and Y.S.O. are either current or former employees of Enanta Pharmaceuticals and received salary and stock compensation during this study. R.M.C., C.M.L, J.D.W, R.K.P., S.R.L., T.S., and R.S.B. received funding from Enanta Pharmaceuticals. R.K.P. reports contract testing from Atea Pharmaceuticals and research support from Gilead Sciences, outside of the described work.
